© 1996 British Society for Rheumatology
other |
COMPARISON OF METHOTREXATE WITH PLACEBO IN THE TREATMENT OF SYSTEMIC SCLEROSIS: A 24 WEEK RANDOMIZED DOUBLE-BLIND TRIAL, FOLLOWED BY A 24 WEEK OBSERVATIONAL TRIAL
*Department of Rheumatology, Daniël den Hoedkliniek Rotterdam
Department of Rheumatology, Medisch Spectrum Twente Enschede
Department of Medical Statistics, University of Nijmegen Nijmegen, The Netherlands
Department of Rheumatology, University Hospital Nijmegen
Correspondence to:
Correspondence to: F. H. J. van den Hoogen, Department of Rheumatology, University Hospital, PO Box 9101, 6500 HB Nijmegen, The Netherlands.
In this study, methotrexate (MTX) was compared with placebo in the treatment of systemic sclerosis (scleroderma, SSc) in a 24 week randomized double-blind trial, followed by an observational trial of 24 weeks duration. Twenty-nine scleroderma patients were allocated to receive weekly injections of either 15 mg MTX or placebo. Patients who responded favourably after 24 weeks continued with the same regimen for a further 24 weeks; those who showed a poor response on placebo were allocated to further treatment with 15 mg MTX weekly, and those who responded poorly to treatment with 15 mg MTX weekly had their doses increased to 25 mg. A favourable response was defined as an improvement of total skin score (TSS) by 
30%, of single breath diffusion capacity (DLco) by 15%, or of the score on a visual analogue scale of general well-being (VAS) by 30%, provided that such improvements were not accompanied by persistent digital ulcerations or worsening of DLco 15%. Seventeen patients were allocated to MTX treatment and 12 to treatment with placebo. After 24 weeks, a significantly larger number of patients receiving MTX (n = 8, 53%) who completed the first 24 weeks of the study had responded favourably compared to patients receiving placebo (n = 1, 10%, P = 0.03). Comparison of separate variables between the two treatment groups by intention-to-treat analysis at week 24 showed improvement in the MTX group of TSS (P = 0.06) and creatinine clearance (P = 0.07). At week 48, 13 patients received MTX from the start of the study and nine during 24 weeks. From these 22 patients, 15 (68%) responded favourably and compared with the start of the study they showed significant improvement of TSS (P = 0.04), VAS (P = 0.02), grip strength of the right hand (P = 0.02) and ESR (P = 0.01). Although the number of patients enrolled in this study is small, these results suggest that in a group of patients with active systemic sclerosis, low-dose MTX seems to be more effective than placebo according to pre-defined response criteria.
KEY WORDS: Systemic sclerosis, Methotrexate, Double-blind placebo-controlled treatment, Side-effects
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  O Kowal-Bielecka, R Landewe, J Avouac, S Chwiesko, I Miniati, L Czirjak, P Clements, C Denton, D Farge, K Fligelstone, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR) Ann Rheum Dis, May 1, 2009; 68(5): 620 - 628. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. KHUDER and B. KAHALEH Statistics and the Relationship of Clinical Research to Clinical Practice J Rheumatol, February 1, 2009; 36(2): 219 - 220. [Full Text] [PDF]
|
|
|
|
|
|
S. R. JOHNSON, B. M. FELDMAN, J. E. POPE, and G. A. TOMLINSON Shifting Our Thinking About Uncommon Disease Trials: The Case of Methotrexate in Scleroderma J Rheumatol, February 1, 2009; 36(2): 323 - 329. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M C Vonk, Z Marjanovic, F H J van den Hoogen, S Zohar, A V M B Schattenberg, W E Fibbe, J Larghero, E Gluckman, F W M B Preijers, A P J van Dijk, et al. Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis Ann Rheum Dis, January 1, 2008; 67(1): 98 - 104. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Blank, R. Max, and H.-M. Lorenz The role of DMARDs in systemic sclerosis therapy Rheumatology, October 1, 2006; 45(suppl_3): iii42 - iii44. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kreuter, T. Gambichler, F. Breuckmann, S. Rotterdam, M. Freitag, M. Stuecker, K. Hoffmann, and P. Altmeyer Pulsed High-Dose Corticosteroids Combined With Low-Dose Methotrexate in Severe Localized Scleroderma Arch Dermatol, July 1, 2005; 141(7): 847 - 852. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. K. Burt, S. Slavin, W. H. Burns, and A. M. Marmont Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure? Blood, February 1, 2002; 99(3): 768 - 784. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Dobbie, J. Lanham, and R. Unwin Morphea presenting as widespread oedema J R Soc Med, January 9, 2002; 95(9): 459 - 460. [Full Text] [PDF]
|
|
|
|
|
|
A. N. Sapadin and R. Fleischmajer Treatment of Scleroderma Arch Dermatol, January 1, 2002; 138(1): 99 - 105. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Binks, J R Passweg, D Furst, P McSweeney, K Sullivan, C Besenthal, J Finke, H H Peter, J van Laar, F C Breedveld, et al. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease Ann Rheum Dis, June 1, 2001; 60(6): 577 - 584. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G Valentini, A Della Rossa, S Bombardieri, W Bencivelli, A J Silman, S D'Angelo, M M. Cerinic, J F Belch, C M Black, P Bruhlmann, et al. European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes Ann Rheum Dis, June 1, 2001; 60(6): 592 - 598. [Abstract] [Full Text] [PDF]
|
|